Within gastrointestinal malignancies, primary hepatocellular carcinoma and pancreatic ductal adenocarcinoma (PDAC) are frequently associated with visceral thromboses (VT). Thrombus formation in the portal (PVT), mesenteric (MVT), or splenic vein (SVT) system leads to portal hypertension and intestinal ischemia. VT in PDAC may convey a risk of increased distal thrombosis and poses therapeutic uncertainty regarding the role of anticoagulation. An increasing number of reports describe VT associated with PDAC. It is possible that early diagnosis of these events may help reduce morbidity and speculatively improve oncologic outcomes. To perform a systematic review to study PVT, MVT, and SVT associated with PDAC, and to provide a comprehensive review. Medline/PubMed, Embase, Web of Science, Scopus, and the Cochrane Library. Data Extraction and Assessment: Two blinded independent observers extracted and assessed the studies for diagnosis of PVT, MVT, and SVT in PDAC. Studies were restricted to English-language literature published between 2007 and 2016. Eleven articles were identified. Five case reports and 7 retrospective studies were found, with a total of 127 patients meeting the inclusion criteria. The mean age at diagnosis was 64 years. PVT was found in 35% (n ¼ 46), SVT in 52% (n ¼ 65), and MVT in 13% (n ¼ 15). Mean follow-up time was 26 months. Only 3 of the selected articles studied the impact of anticoagulation in VT. All patients with nonvisceral thrombosis (eg, deep-vein thrombosis, pulmonary emboli) were therapeutically treated; in contrast, patients with VT only rarely received treatment. VT in PDAC is a frequent finding at diagnosis or during disease progression. Evidence to guide treatment choices is limited, and current management is based on inferred experience from nononcologic settings. Anticoagulation appears to be safe in VT, with most of the large studies recommending a careful assessment for patients at a high risk of bleeding.
Introduction
The word splanchnic derives from the Greek splanchnikos, from splanchna, plural of "viscera."
1 Thus, the terms "visceral vein thromboses" or "splanchnic vein thromboses" are commonly used in medical terminology to refer to thromboses in, near, or pertaining to the viscera or intestines, while "visceral" relates to the internal organs of the body.
Here we refer to visceral thromboses (VT) as the involvement of the abdominal veins (portal, splenic, mesenteric) ( Figure 1 ). Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related death in the United States, 2 and it is one of the most common malignancies associated with thrombotic events, [3] [4] [5] [6] with an estimated incidence of 36% in a large single-institution cohort of 690 patients with PDAC. 7 Retrospective analyses have found that the most common thrombotic complications include deep-vein thrombosis and pulmonary emboli, which have an almost equal incidence (46% vs. 39%) 8 ; catheter-related thrombosis (15%) incidentally discovered on routine surveillance and restaging scans.
14 With such incidental discoveries, and given the lack of therapeutic guidelines for VT management, there are significant uncertainties related to the potential increased risk of complications, reduced survival, and inferior prognosis. 14, 15 In this systematic review, we examine the most recent published literature on VT specifically pertaining to PDAC, and assess its clinical implications and prognosis.
Portal Venous System
Portal Vein Thrombosis PVT is the formation of a thrombus that partially or completely occludes the portal vein (PV), the latter of which is formed by the confluence of the splenic vein (SV) and the superior mesenteric vein (MV). 16 The thrombus can arise in the trunk of the PV and can extend into the intrahepatic branches. 17 PVT is the best-studied and described site of VT, most notably as a result of the increased incidence in patients with liver cirrhosis, inherited thrombophilic disorders, and malignancies. The prevalence increases with the severity of cirrhosis: it is 1% to 16% in compensated cirrhosis 18 and 35% in patients with decompensated cirrhosis and hepatocellular carcinoma. 19, 20 PVT is commonly considered acute if presentation is within 60 days and chronic if it has been present for > 60 days. However, when chronic, it may induce complications due to portal hypertension with worsening ascites, splenomegaly, and variceal bleeding. 21 PVT has been classified into 4 categories depending on the extent of thrombosis, as follows. Type I is limited to PV. Type II includes extension into superior MV, but vessels are patent. Type III includes diffuse thrombosis of splanchnic venous system with large collaterals. Finally, type IV includes extensive splanchnic venous thrombosis but with only fine collaterals. 22 Chronic PV obstruction can lead to the development of multiple collateral vessels, known as cavernous transformation.
23
The long-term sequelae of PVT include portal hypertension, which in patients with pancreatic adenocarcinoma has been shown to significantly contribute to ascites formation. One study found that 82% of patients with PDAC and ascites had a serumeascites albumin gradient of 1.1; the authors concluded that VT and tumor burden were possible causes of increased ascites formation in this population. 24 Commonly with intra-abdominal diseases, thrombosis will originate in large veins at the site of compression and will later progress peripherally to involve smaller vessels. In contrast, thrombosis due to hematologic disorders typically affects the smaller vessels and then progresses to larger trunks. 25 
Mesenteric Vein Thrombosis
The MV is anatomically divided into superior and inferior MVs, in which the former drains into the SV. 16 Mesenteric vein thrombosis (MVT) can be defined as primary if not associated with any other disease and secondary if attributed to an acquired etiology 
Thromboses in Pancreas Adenocarcinoma
(eg, malignancy, thrombophilia). MVT is typically associated with nonspecific symptoms, may be difficult to diagnose, and has low awareness among clinicians. 26 It can also be an uncommon cause of mesenteric ischemia in 5% to 15% of cases. 27 According to a Swedish autopsy registry study, its prevalence is 12%, in which 6 of 51 patients had an underlying pancreatic malignancy. 28 Common presentations include acute abdominal symptoms, particularly in patients with prior thrombotic episodes or documented coagulopathy. 29 Currently MVT is classified as acute, subacute, and chronic. 30 Acute MVT accounts for 6% to 9% of all cases and typically presents with severe abdominal pain that is out of proportion to physical examination results; chronic MVT accounts for 20% to 40% of the cases and is associated with vague and nonspecific abdominal discomfort. 31 
Splenic Vein Thrombosis
Anatomically, the SV arises by the union of smaller vein branches from the stomach, pancreas, and large intestine (via the inferior MV). 16 It is associated with the posterior surface of the tail and body of the pancreas from the hilum of the spleen to its junction with the superior MV, where it forms the PV. 32 It was originally described as a cause of gastrointestinal bleeding, 33 but it was later observed to be a frequent thrombosis site owing to its close vicinity to the pancreas, 32 inflammation from pancreatitis, 34 and direct tumor invasion or compression, 35 as well as being a consequence of direct trauma and pseudocyst formation. 32 The foremost hazard of splenic vein thrombosis (SVT) is gastrointestinal bleeding due to the generation of localized portal hypertension, which is referred as sinistral, 36 or left-sided. 37 Most of the currently available evidence is connected to pancreatitis-induced SVT. 34, [38] [39] [40] A meta-analysis by Butler et al 39 found that the overall incidence of SVT in the noncancer setting was 14.1% and the overall rate of gastrointestinal bleeding was 12.3%. In contrast, SVT in PDAC has not been frequently studied, and few data exist. A retrospective study by Dedania et al 35 that evaluated SVT in PDAC evaluated 70 patients who underwent surgery for pancreatic exocrine cancer. In the cohort, 27 patients had SVT, 46% (n ¼ 12) had resectable disease (stage IA/IB, IIA), and 54% had locally advanced disease (IIB/III). PDAC was identified in 19 patients (70%). In this study, the authors concluded that SVT was correlated with higher rates of intraoperative blood loss, pancreas-specific complications, and a reduced long-term survival rate. This highlights the significance of SVT in the preoperative evaluation of patients with PDAC as well as the potentially increased risk of associated intraoperative complications.
Radiographic Diagnosis
Computed tomography (CT) is the imaging modality of choice for the diagnosis of VT. To make a correct diagnosis, radiologists need to rely on radiographic features to distinguish between bland thrombi (the result of a hematologic disorder) versus tumor thrombus (malignant thrombi), 25 which often can be technically difficult to interpret, as no parameter is entirely specific. Several radiographic criteria were proposed by Tublin et al 41 to differentiate between benign and malignant thrombi (Figures 2-4) , including mural signs (eg, halo sign, abnormal wall enhancement), vascular signs (eg, venous filling defect, vein enlargement, venous engorgement), and extramural nonvascular signs (eg, mesenteric fat edema, bowel dilation). 25 The precise interpretation of the thrombus etiology has direct therapeutic implications for the oncologic patient.
Anticoagulation
The presence of thrombus within the visceral veins may represent a clinical challenge for treatment decisions, particularly in view of concomitant cancer progression and the prothrombotic state that 
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Clinical Colorectal Cancer June 2018 -e209 often accompanies PDAC. 42, 43 Consequently, this can theoretically lead to intestinal or splenic infarction and thus portend an increased risk of gastrointestinal bleeding with a potential risk of death. [44] [45] [46] Hence, the purpose of anticoagulation is not only thrombus dissolution and recanalization, but also the prevention of progression to cavernous transformation of the PV and thus a reduced risk of portal hypertension. 23, 47, 48 Current therapeutic strategies follow the recommendations made by the American College of Chest Physicians (ACCP) 49 for venous thromboembolism (VTE); however, evidence from this guideline does not specifically address the use of anticoagulation in circumstances like VT. Use of anticoagulation is not standardized, and questions about whether to provide anticoagulation therapy pertain to the type of treatment, the duration of therapy, and the overall context of prognosis. These uncertainties, as well as the lack of guidelines, collectively contribute to challenging decision making in this setting. 50 Currently, most treatment algorithms regarding VT are extrapolated from studies based on patients with liver cirrhosis with or without hepatocellular carcinoma, 13, 18, 19, [51] [52] [53] owing to the increased incidence of VT in liver cirrhosis compared to PDAC. If acute PV, MV, or SV thromboses are present in patients with malignancy, anticoagulation is generally recommended, preferably with either low-molecular-weight heparin (LMWH) or unfractionated heparin, 54, 55 given the strong evidence of greater efficacy and safety in contrast to oral vitamin K antagonists. 56 In the noncancer setting, the duration of treatment should be at least 3 months as per current guidelines by ACCP, 49 with goals to halt thrombus extension, achieve vein recanalization, and prevent portal hypertension and intestinal ischemia, 26 as the latter can be fatal.
Currently, expert opinion recommends at least 6 months of LMWH monotherapy. 57 Plessier et al 46 found that recanalization occurred in one-third of patient receiving early anticoagulation and therefore supported early anticoagulation of patients with acute PVT; nonetheless, if SVT and ascites were detected on imaging, recanalization with anticoagulation was unlikely.
Role of Newer Anticoagulants
After the introduction of the newer oral anticoagulants (NOACs; eg, dabigatran, apixaban, rivaroxaban), recent data have reported on their application in oncologic patients. [58] [59] [60] [61] These novel anticoagulants are attractive to patients and clinicians because of the ease of oral administration and the absence of the need for laboratory monitoring, 62 making them attractive alternatives to LMWH. Currently outcome data on these agents in the cancer setting are limited, and there is only one approved reversal agent, idarucizumab. 63 Cancer patients pose several unique challenges to anticoagulation (AC) therapy, primary as a result of disease progression, which can affect organs (eg, kidney or liver) that can limit therapeutic choices, 58 and which as a result of anticancer therapies have significant interactions with the CYP3A4 enzyme and/or p-glycoprotein transporter, 64, 65 which can modify pharmacologic clearance, resulting in an increased predisposition to bleeding complications. recommended the consideration of long-term anticoagulation for all patients with visceral thrombi, with treatment decisions to be made on a case-by-case basis by balancing risk factors for recurrence (eg, underlying prothrombotic conditions) and the risk of bleeding. Therefore, NOACs appear to be an attractive alternative to providing long-term anticoagulation for VT. However, because at present the evidence is limited, we cannot recommend their use as the standard of care because there is little evidence of their safety and efficacy.
Methods
The primary objective of this systematic literature review was to identify the most recent available evidence pertaining to diagnosis, treatment, and management of VT in PDAC. Our hypothesis was that currently there are few published data pertaining to this topic, and clinical management lacks appropriate recommendations. Therefore, we anticipate that this review will increase clinical awareness and encourage further study of VT in PDAC. This review followed the elements of PICOS methodology (Table 1) .
Searching Methods
Systematic literature searches were conducted (February 2
For the following databases, both controlled vocabulary and text words were used in the development of the search strategies: Medline/PubMed, Embase, Cochrane Library. All search results were combined in a bibliographic management tool (EndNote), and duplicates were eliminated both electronically and manually.
The search strategy had 2 major components that were linked together using the AND operator: (1) pancreatic cancer terms including adenocarcinoma, glandular tumor; (2) intra-abdominal thrombosis terms including portal vein thrombosis, PVT, venous thromboembolism, VTE, venous thrombosis, thrombotic events, and thromboembolic events. Comprehensive searches were also conducted in 2 gray-literature sources to incorporate this perspective to the final qualitative synthesis of the investigation: the Grey Literature Report and Open Grey. Table 2 lists the eligibility criteria. Data extraction was performed by one of the reviewers (A.M.H.) blinded to the names of authors, institutions, and journal titles for the included studies, who extracted the relevant data. The following information was extracted from each article: authors, year of publication, study type, country of origin, mean patient age, primary working hypothesis, and outcomes.
Inclusion Criteria and Data Extraction
Analyses of included studies and included patients (Table 3) and overall treatment and outcomes from studies (Table 3) were performed. Disagreements between the 2 reviewers (A.M.H., E.O.R.) were resolved by discussion and analysis of the data.
This article is reported in accordance with the guidelines set out by Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA).
Results
The flow diagram of the study selection is shown in Figure 5 . A total of 10 articles were identified from the electronic search. After screening the articles, 9 articles on VT in PDAC were included, and their data were extracted. Two other articles were added after reference search by the authors' criteria. 67, 68 Overall, these 11 articles included a total of 127 patients with thromboses (PVT, SVT, MVT). There were no randomized controlled studies. 67 3-month survival after cancer diagnosis was 35% in the group with VT compared to 53% in patients without VT.
Other pertinent large studies related to VT that involved a diverse cohort are listed in Table 4 . The largest studies were by Ageno and colleagues, 55, 77 who performed a prospective cohort study of 604
patients from 2008 to 2014 with splanchnic vein thrombosis (22.7% of cohort had solid cancer). This study demonstrated first that there were no higher rates of hemorrhage between those who received anticoagulants compared to those who did not (77% of the total cohort was treated with AC), and second supported the safety and efficacy of AC in most patients with VT. However, the main end point of this study was to assess the incidence of bleeding, mortality, and thrombotic events, and it did not evaluate survival in cancer patients.
Discussion
VT is an emergent topic in the literature. 50, 55, 66, 67, [76] [77] [78] [79] [80] [81] As a result of the heterogeneity of presentation, thrombosis can be discovered incidentally through the course of the disease, in particular in patients with advanced metastatic disease, or thrombosed patients may present with symptoms that lead to further abdominal imaging. With this systematic review and literature analysis, we confirmed the significant occurrence of VT in PDAC. However, there are no standard therapeutic guidelines. Recently published studies have recognized that VT is a prognostic factor for short-term survival 67 and is a marker of occult cancer. 76 In a retrospective study, Menapace at al 14 identified from a cohort of 135 patients with PDAC, 31 (22.9%) with VT. This analysis confirmed that in PDAC, the occurrence of VT was Selected studies were considered eligible if all of the following predefined criteria were met:
1. Studies were related to portal vein, mesenteric vein, and/or splenic vein thrombosis.
2. Pathologic confirmation of pancreas adenocarcinoma.
3. Year of publication 2007 or later. 4 . Studies reported in English language.
Full text publications.
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Clinical Colorectal Cancer June 2018 -e211 significantly associated with worse survival (hazard ratio ¼ 2.6; 95% confidence interval, 1.6-4.2; P < .0001). This finding has clinical importance in the context of disease progression. In the same study, patients with advanced disease were strongly correlated with a greater proportion of VT. There were only 11 patients with localized disease (stage IB, n ¼ 2; stage IIB, n ¼ 4; stage III, n ¼ 5) and VT; in contrast, 32 patients had advanced stage disease (stage IV). However, 4 patients with localized disease underwent pancreatic resection with thrombus involvement. In PDAC, especially of the head of the pancreas, tumor can frequently invade the superior MV and PV from direct tumor extension. This vascular invasion is an important parameter for determining surgical resectability. Therefore, it is common when performing initial staging or subsequent imaging studies to discover thrombi within the visceral vein. These thrombi can be either bland or tumor related, which can sometimes be differentiated by on the basis of CT imaging characteristics. 41 A bland thrombus is defined as a benign filling defect that can be idiopathic or can reflect an hypercoagulable state, venous stasis, or the presence a foreign body. 82 In contrast, a malignant filling defect or tumor thrombus should be considered when the thrombus itself shows continuity within the primary mass and enhancement of the filling defect. 82, 83 Additionally, it is important to know that both types of thrombi (bland and tumor) can coexist as a result of the innate hypercoagulable state and from the external compression of a vein (eg, PV, MV, SV) by the underlying malignancy. 4, 84 Recent research has explored the significance of incidental VT, which is increasingly discovered during routine CT imaging. Mean duration of AC was 13.9 mo. Incidence for major bleeding was 3.9 per 100 patient-years (2.6-6.0) and 5.6 per 100 patient-years (3.9-8.0) for thrombotic events.
Did 
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Currently, the subcommittee on Hemostasis and Malignancy has recommended use of the term "incidental" and recommended against the use of the term "asymptomatic," 86 particularly because retrospective studies have shown that many of these events are indeed symptomatic and can primarily be attributed to the malignancy itself. 86 Evidence supporting therapeutic anticoagulation for incidental VT in cancer patients is not yet clear. ACCP guidelines recommend AC for symptomatic venous thrombosis patients, and no AC for asymptomatic patients with incidentally detected events. 49 Conversely, the American Association for the Study of Liver Diseases recommends AC in PVT (acute or chronic) and Budd-Chiari syndrome. Long-term AC should be reserved for patients with permanent thrombotic risk factors and in the absence of other contraindications. 87 At Memorial Sloan Kettering Cancer Center, for patients with an acute VT, we typically initiate anticoagulation with a direct oral anticoagulant when the risks are deemed to outweigh the benefits, and when the patient is otherwise a candidate for active therapy. For patients with chronic thrombosis, the decision to anticoagulate is made on a case-by-case basis. Of particular significance is the setting of locally advanced or recurrent PDAC, where varices may develop related to portal hypertension in the setting of chronic visceral vein thromboses. These decisions are nuanced and complex, and they pertain to balancing risks of anticoagulation and bleeding.
Currently there is no meaningful evidence supporting the use of primary prophylaxis in this setting. However, taking into account that most visceral thrombi are diagnosed in advanced-stage cancer, and there is indirect evidence pointing toward a decrease in survival, anticoagulation should be considered on a case-by-case basis.
Conclusion
With the aid of increased incidence of diagnostic imaging, incidental VT is a topical issue in the literature. 50, 55, 66, 67, [76] [77] [78] [79] [80] [81] There is ongoing discussion regarding whether AC is indicated. Extrapolated evidence from patients with no malignancy has not clearly demonstrated a favorable impact from anticoagulation with LMWH and improved prognosis. Recommendations are weak as a result of the observational nature of the data, the infrequent finding of VT, and the limited overall survival in PDAC. Controlled prospective studies are needed to provide a framework for decision making regarding anticoagulation of PVT, MVT, or SVT regarding safety and prevention of longer-term complications. Pending evidence from the use of novel oral anticoagulants will provide an additional choice for management of VT. Moreover, prospective research studies should describe outcomes and management of VT on the bases of vein location, treatment algorithm, and cancer stage.
Clinical Practice Points
Pancreas adenocarcinoma is a well-known risk factor for development of VT. VT is a poor prognostic indicator for short-term survival.
14,81
In order of incidence, PV, SV, and MV account for most of VT. Incidental or nonincidental VT should be treated with LMWH if there are no contraindications (eg, active bleeding, severe thrombocytopenia, end-of-life care).
The exact role of anticoagulation in the setting of VT with regard to oncologic outcome and prevention of complications remains to be fully defined.
